Product Description
OTO-510 is being developed by Otonomy for prevention of hearing loss due to chemotherapy with cisplatin (CIHL). (Sourced from: https://www.otonomy.com/pipeline/)
Mechanisms of Action: Gene Therapy
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: Injection, Otic
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Otonomy
Company Location: SAN DIEGO CA 92121
Company CEO: David A. Weber
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Hearing Loss
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/29/2023 |
News Article |
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board |
|
01/06/2022 |
News Article |
Otonomy Reports Corporate and Product Pipeline Update |
|
10/27/2021 |
News Article |
Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting |
|
02/17/2021 |
News Article |
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting |